Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression

NCT02309658 is registered in ClinicalTrials.gov with Professor Fernando Figueira Integral Medicine Institute as lead sponsor.

NCT NCT02309658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02309658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression
Lead sponsor
Professor Fernando Figueira Integral Medicine Institute
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
October 31, 2015
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of cervix